PRO-RABEPRAZOLE TABLET (ENTERIC-COATED)
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
05-09-2019
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
RABEPRAZOLE SODIUM
Tilgjengelig fra:
PRO DOC LIMITEE
ATC-kode:
A02BC04
INN (International Name):
RABEPRAZOLE
Dosering :
20MG
Legemiddelform:
TABLET (ENTERIC-COATED)
Sammensetning:
RABEPRAZOLE SODIUM 20MG
Administreringsrute:
ORAL
Enheter i pakken:
10/100/500
Resept typen:
Prescription
Terapeutisk område:
PROTON-PUMP INHIBITORS
Produkt oppsummering:
Active ingredient group (AIG) number: 0143681002; AHFS:
Autorisasjon status:
CANCELLED POST MARKET
Autorisasjon dato:
2023-07-10
Preparatomtale
PRODUCT MONOGRAPH
PR
PRO-RABEPRAZOLE
Rabeprazole Sodium Enteric-Coated Tablets
10 mg and 20 mg
H
+
,
K
+
-ATPASE INHIBITOR
DATE OF REVISION:
September 5, 2019
PRO DOC LTÉE
2925, boul. Industriel,
Laval, Quebec
H7L 3W9
_Control #: 230299_
Rabeprazole pm en
Pg. 1
_PRO-RABEPRAZOLE Product Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
................................................................................23
PHARMACEUTICAL INFORMATION
..........................................................................23
CLINICAL TRIALS
..........................................................................................................24
DETAILED PHARMACOLOGY
.......................................
Les hele dokumentet
